Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

UNKNOWN × Small Cell Lung Carcinoma × anlotinib × Clear all

Phase

Status

Sponsor Class

OTHER 13 INDUSTRY 2 UNKNOWN 1 OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Nasopharyngeal Carcinoma 1 Head and Neck Neoplasms 1 Breast Neoplasms 1

Interventions

apatinib 2 Etoposide 2 tislelizumab 1 camrelizumab 1 anlotinib 1 Radiotherapy 1 Irinotecan 1 Immunotherapy 1 Drug Therapy 1 Cisplatin 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04620837 2020-11-09

Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy

ChineseAMS

Phase 2 Unknown

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡